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atric hospitalizations. Wilcoxon rank sum test was used to determine differences 
in hospital LOS. Results: Overall, these data represent over 4.6 million pediatric 
hospital discharges for SSTIs nationwide from 2001 to 2010. The rate of hospitaliza-
tion for SSTIs increased 60%, from 491/10,000 in 2001 to 784/10,000 in 2010. S. aureus 
SSTIs increased over the study period from 6/10,000 in 2001 and peaked at 37/10,000 
in 2008. This was mostly attributable to the dramatic increase in MRSA SSTIs, from 
1.3 cases per 10,000 in 2001 to 31.4 cases per 10,000 in 2010. Additionally, MSSA SSTIs 
nearly tripled throughout the study period (4 per 10,000 in 2001 to 12 per 10,000 in 
2010). The median (interquartile range) hospital LOS for S. aureus SSTIs significantly 
decreased from 3 (2-5) days in 2001 to 2 (1-3) days in 2010 (P< 0.001). ConClusions: 
The incidence of MSSA and MRSA SSTI hospitalizations among U.S. children has 
dramatically increased from 2001 to 2010.
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objeCtives: To characterize types of hospitals and patients contributing to the 
prevalence of ABSSSI hospital admissions and describe recent admission trends in 
the US. Methods: We conducted a retrospective database analysis of adult (≥ 18 
years) hospital admissions with a principal ICD-9 diagnosis of ABSSSI: 681.XX, 682.
XX, 686.XX, 958.3, 998.5X, or 035 using the US Healthcare Cost and Utilization Project 
National Inpatient Sample (HCUP NIS), representing over 1,000 hospitals with > 8 
million hospital stays annually from 2005-2011. Descriptive and bivariate analysis 
was performed. HCUP specified weights were used for national estimates. Results: 
From 2005-2011, there were 4,891,187 adult ABSSSI hospital admissions (2% of all 
HCUP NIS admissions), with admissions increasing 17.3% across this timeframe 
(p< 0.0001). ABSSSI patients were primarily male (50.8%), white (60.3%), mean age 
55.7 years (±18.6 yrs), Medicare (40.7%), and discharged to home (53.8%). Patients 
were of moderate severity of illness (43.5% APR-DRG II) with minor risk of mortality 
(60.4% APR-DRG I). Comorbidities included diabetes without complications (25.2%), 
COPD (17.2%), and CHF (10.3%) and increased over time (p≤ 0.0001). Hospitals were 
in urban areas (85.4%), in the South (39.0%), of large bed size (> 325 beds by region, 
59.1%), private (71.0%), and with non-teaching status (55.3%). Majority of admissions 
were other cellulitis and abscess (682.XX, 73.5%) and post-operative wound infection 
(998.5X, 21.5%). Post-traumatic (958.3, n= 13,952) and post-operative wound (998.5X, 
n= 1,048,916) infection incurred the greatest mean length of stay (7.2 vs 6.7 days, 
respectively vs 4.7 days average across ABSSSI codes). Mortality was 0.5% overall and 
was highest among post-operative wound infection patients (1.1%). ConClusions: 
More ABSSSI patients enter the US hospital system each year with a greater propor-
tion having comorbidities. As the population continues to age, alternative settings 
for treating ABSSSI patients may lessen the burden on the hospital system and 
reduce potential risks associated with a hospital stay.
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objeCtives: Infants are at greatest risk for severe pertussis (~50% of infant cases 
require hospitalization). Recent surveillance indicates a resurgence of overall per-
tussis incidence in the US, but limited data exist on whether severe infantile cases 
are also resurging and the extent to which severe pertussis incidence in infants var-
ies by sex and race. We therefore assessed recent US trends in overall and sex- and 
race-stratified incidence of infant pertussis-related hospitalizations. Methods: 
Data on pertussis-related hospitalizations (ICD-9-CM discharge codes 033.0, 033.8, 
033.9, 484.3) from the 2000-2011 Nationwide Inpatient Sample (NIS) were retrospec-
tively analyzed. Annual pertussis-related hospitalizations per 10,000 infants aged 
< 12 months was estimated using NIS sampling weights and year-specific population 
denominators from US census data. Results: Incidence of pertussis-related hos-
pitalization was ~6/10,000 infants between 2000 and 2003 before increasing sharply 
in 2004 (9.0/10,000) and 2005 (13.8/10,000). Thereafter, incidence fell substantially 
(6.2, 4.1, and 4.2/10,000 in 2006, 2007, and 2008, respectively) before increasing again 
in 2009 and 2010 (5.9 and 7.8/10,000, respectively). Incidence declined again in 2011 
(3.2/10,000). Incidence was similar between males and females, but substantial dif-
ferences were observed by race. Incidence was highest in Hispanic infants, starting 
at 8.6/10,000 in 2000, peaking at 24.9/10,000 in 2005, and then falling to 4.3/10,000 
in 2008 before another sharp increase to 14.7/10,000 in 2010. Incidence was lowest 
for white and Asian infants, reaching a 2005 peak of only 5.4 and 5.3/10,000, respec-
tively. ConClusions: Infant pertussis hospitalizations peaked in 2005 before a 
sharp decline thereafter, possibly due to increased herd immunity conferred by 
the 2006 launch of universal adolescent Tdap vaccination. Incidence resurged again 
through 2010 before another decline in 2011, demonstrating for severe cases the 
documented cyclic pattern of peaks and nadirs for overall pertussis incidence. This 
analysis also highlights the need for increased focus on minorities in pertussis 
vaccination programs.
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ASSeSSING lyMe dISeASe PRevAleNce IN tHe uNIted StAteS MedIcAId 
PoPulAtIoN
Wang L.1, Xie L.2, Dysinger A.H.2, Zhang J.1, Shrestha S.1, Wang Y.2, Kariburyo M.F.2, Baser O.3
1STATinMED Research, Dallas, TX, USA, 2STATinMED Research, Ann Arbor, MI, USA, 
3STATinMED Research and The University of Michigan, Ann Arbor, MI, USA
objeCtives: To examine the geographic, age, gender and racial variations in 
the prevalent population of Lyme disease using U.S Medicaid data. Methods: 
Patients with Lyme disease were identified using International Classification of 
and deaths, respectively, may have been QIV-preventable. ConClusions: The 
seasonal variability of influenza B lineage circulation and the level of vaccine 
match determine the extent of the benefit of QIV use. However, on average, under 
reasonable assumptions of vaccine effectiveness, a substantial number of hospi-
talizations and deaths could have been prevented by using QIV during the study 
period in the United States. Funding: GlaxoSmithKline Biologicals SA
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objeCtives: We determined the association between interferon treatment for 
chronic hepatitis C (HCV) and the presence and severity of metabolic and vas-
cular complications over time in a high-risk Medicaid population. Methods: 
This was a historical prospective cohort study using administrative claims data 
of Maryland Medicaid recipients (2006-2009) infected with hepatitis C. We used 
the validated Diabetes Complications Severity Index (DCSI) as proxy for the pres-
ence and severity of metabolic and vascular complications. The endpoint of the 
study was the change in DCSI score during three years of follow-up. At baseline, 
interferon-treated patients were matched 1:10 to non-treated patients for DCSI 
count, cirrhosis, end stage liver disease, race, and anti-diabetic therapy. We modelled 
the association between interferon use and the risk of the presence and increased 
severity of vascular and metabolic complications using a zero-inflated Poisson mul-
tivariate regression, stratified by White and Black race and adjusted for baseline 
covariates. Results: White persons treated with interferon for 24-48 weeks and 
longer than 48 weeks had a significantly smaller increase in DCSI score ranging 
from 53%-75% and 54%-69% over the study follow-up, respectively, compared to 
untreated persons. There was no significant difference in the change in DSCI scores 
in Blacks treated for either 24-48 weeks or longer than 48 weeks, though paradoxi-
cally Blacks treated for > 48 weeks had a borderline significant 45% higher DSCI 
score at 30 months of follow-up. In patients with a DSCI count of zero at baseline, 
both White (OR= 0.22, P= 0.01) and Black (OR= 0.38, P= 0.09) patients treated with 
interferon exhibited a lower risk of developing vascular/metabolic disease at 30 
and 36 months of follow-up, respectively. ConClusions: The results suggest that 
interferon treatment for chronic HCV might decrease metabolic and vascular com-
plications related to diabetes.
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objeCtives: Hepatitis C decreases health related quality of life (HRQL) which 
is further diminished by dual antiviral therapy. HRQL improves after successful 
treatment. This trial explores the course of and factors associated with HRQL in 
patients given individualized or standard treatment based on early treatment 
response. To study the relationship betweenv HRQL and mode of acquisition, treat-
ment discontinuations and treatment outcome in patients with chronic hepatitis 
C. Methods: The Short Form SF-36 Health Survey was administered for evaluation 
health-related quality of life. Consecutive unselected Kazakh patients with chronic 
hepatitis C completed the SF-36 questionnaire before, during and after treatment 
with pegylated interferon and ribavirin before, during and after combination ther-
apy. Results: At baseline, HRQL was reduced in all SF-36 subscales in our patients 
as compared with the general Kazakh population by age, participating center, sever-
ity of liver disease and income. Exploring the course of HRQL (scores at follow up 
minus baseline), only the dimension general health increased. In this dimension 
patients with a relapse or sustained response differed from non-responders. Men 
and women differed in the dimension bodily pain. Treatment schedule did not influ-
ence the course of HRQL. ConClusions: Kazakh patients with chronic hepatitis 
C have a marked reduction in their HRQL as compared to the general population. 
Main determinants of HRQL were severity of liver disease, age, gender, participating 
center and response to treatment. Our results do not exclude a more profound nega-
tive impact of individualized treatment compared to standard, possibly caused by 
higher doses and extended treatment duration in the individualized group. Antiviral 
therapy might have a more intense and more prolonged negative impact on females. 
Early dropouts from therapy have significantly lower HRQL scores at baseline than 
adherent patients, and sustained viral responders improve their HRQL significantly 
more than non-responders.
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objeCtives: Estimating the burden of Staphylococcus aureus infections among U.S. 
children is important for planning appropriate prevention and treatment strategies. 
The objectives of this study were to characterize national estimates of S. aureus 
SSTIs in pediatric patients from 2001 to 2010 and assess trends in hospital length 
of stay (LOS). Methods: This was a retrospective analysis of the U.S. National 
Hospital Discharge Surveys from 2001 to 2010. Eligible cases included children < 
18 years of age hospitalized with a principle ICD-9-CM diagnosis code for SSTI. 
S. aureus, methicillin-susceptible S. aureus (MSSA), and methicillin-resistant S. 
aureus(MRSA) were defined by ICD-9 CM diagnosis codes. Data weights were used 
to derive national estimates. Annual incidence rates were reported per 10,000 pedi-
